$83.37 Million in Sales Expected for AngioDynamics, Inc. (ANGO) This Quarter
Equities research analysts forecast that AngioDynamics, Inc. (NASDAQ:ANGO) will announce $83.37 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for AngioDynamics’ earnings, with the highest sales estimate coming in at $83.44 million and the lowest estimate coming in at $83.30 million. AngioDynamics posted sales of $85.41 million in the same quarter last year, which suggests a negative year-over-year growth rate of 2.4%. The business is expected to announce its next quarterly earnings results on Thursday, September 27th.
According to Zacks, analysts expect that AngioDynamics will report full year sales of $347.64 million for the current financial year, with estimates ranging from $345.00 million to $350.27 million. For the next financial year, analysts expect that the firm will report sales of $354.19 million per share, with estimates ranging from $350.30 million to $358.08 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for AngioDynamics.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, July 11th. The medical instruments supplier reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.01). The business had revenue of $88.30 million for the quarter, compared to analyst estimates of $89.02 million. AngioDynamics had a return on equity of 5.21% and a net margin of 4.74%. The company’s revenue for the quarter was up 1.6% compared to the same quarter last year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANGO. JPMorgan Chase & Co. raised its stake in AngioDynamics by 958.2% during the first quarter. JPMorgan Chase & Co. now owns 895,414 shares of the medical instruments supplier’s stock worth $15,447,000 after acquiring an additional 810,794 shares during the period. Tributary Capital Management LLC acquired a new stake in shares of AngioDynamics in the second quarter valued at approximately $9,681,000. Segall Bryant & Hamill LLC increased its stake in shares of AngioDynamics by 141.1% in the first quarter. Segall Bryant & Hamill LLC now owns 651,782 shares of the medical instruments supplier’s stock valued at $11,243,000 after purchasing an additional 381,497 shares during the period. BlackRock Inc. increased its stake in shares of AngioDynamics by 7.3% in the second quarter. BlackRock Inc. now owns 5,478,788 shares of the medical instruments supplier’s stock valued at $121,848,000 after purchasing an additional 374,834 shares during the period. Finally, Heartland Advisors Inc. acquired a new stake in shares of AngioDynamics in the first quarter valued at approximately $5,990,000. Hedge funds and other institutional investors own 98.18% of the company’s stock.
ANGO opened at $23.99 on Friday. The stock has a market cap of $875.35 million, a P/E ratio of 32.34 and a beta of 0.93. AngioDynamics has a fifty-two week low of $15.16 and a fifty-two week high of $24.24. The company has a current ratio of 2.93, a quick ratio of 2.08 and a debt-to-equity ratio of 0.16.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Featured Article: Hedge Funds – How They Work For Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.